The Active After Cancer Trial (AACT)
AACT
Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)
1 other identifier
interventional
120
1 country
9
Brief Summary
This study is being done to determine whether a telephone-based counseling intervention can help survivors of breast and colorectal cancer increase their weekly physical activity. Observational evidence suggests that physical activity after breast and colorectal cancer diagnosis decreases recurrence rates. Unfortunately, many people become less active during cancer therapy, and a substantial proportion never return to pre-diagnosis levels of physical activity. This study looks to see if people who have recently finished chemotherapy for breast, colon or rectal cancer can be motivated to increase their exercise by talking to an exercise specialist over the phone. The study also looks at changes in mood, fatigue, fitness, fat distribution and weight.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable breast-cancer
Started Oct 2007
Longer than P75 for not_applicable breast-cancer
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2007
CompletedFirst Submitted
Initial submission to the registry
October 22, 2007
CompletedFirst Posted
Study publicly available on registry
October 23, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
ExpectedFebruary 23, 2026
February 1, 2026
1.4 years
October 22, 2007
February 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate the ability of a multi-center, telephone-based physical activity intervention to increase weekly physical activity levels in sedentary patients treated with adjuvant chemotherapy for Stage I-III breast or colorectal cancer.
months
Secondary Outcomes (1)
To evaluate the impact of a physical activity intervention upon fitness, exercise self-efficacy, anthropometric measures, and quality of life in a group of patients with stage I-III breast or colorectal cancer.
months
Study Arms (2)
1
EXPERIMENTALImmediate participation in a 16-week exercise program
2
NO INTERVENTIONControl population; will receive exercise plan after 16-week control period
Interventions
Eligibility Criteria
You may qualify if:
- Histologically confirmed stage I-III breast or colorectal cancer
- years of age or older
- Completed adjuvant treatment(for current malignancy)
- Completion of all adjuvant chemotherapy and radiation (with the exception of adjuvant herceptin and/or tamoxifen/aromatase inhibitor therapy for breast cancer patients) between 2 and 36 months prior to enrollment
- Ability to speak and read English
- Willingness to be randomized
- Medical clearance from an oncologist or primary care physician stating the participant is able to participate in an unsupervised, moderate-intensity physical activity program
- No major surgery within 2 months of study enrollment or planned during study period
You may not qualify if:
- Metastatic cancer
- Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements
- Plans to have hip or knee replacement within a year
- Participation in more than 60 minutes a week of moderate-intensity recreational activity as assessed by the International Physical Activity Questionnaire Short Form
- BMI \>47
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dana-Farber Cancer Institutelead
- Cancer and Leukemia Group Bcollaborator
Study Sites (9)
University of California at San Diego
La Jolla, California, 92093, United States
University of California San Francisco
San Francisco, California, 94143, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
New Hampshire Oncology Hematology
Concord, New Hampshire, 03106, United States
Lakes Regional Healthcare Hematology Oncology
Hooksett, New Hampshire, 03106, United States
Rosewell Park Cancer Institute
Buffalo, New York, 14263, United States
Hematology Oncology Associates of Central New York
East Syracuse, New York, 13057, United States
Ohio State University
Columbus, Ohio, 43210, United States
Vermont Cancer Center
Burlington, Vermont, 05401, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jennifer Ligibel, MD
Dana-Farber Cancer Institute
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
October 22, 2007
First Posted
October 23, 2007
Study Start
October 1, 2007
Primary Completion
March 1, 2009
Study Completion (Estimated)
December 1, 2026
Last Updated
February 23, 2026
Record last verified: 2026-02